A new study has raised serious concerns about what happens when patients stop taking popular GLP-1 drugs, often used for diabetes and weight loss. The findings suggest that the cardiovascular benefits may vanish, nearly doubling the risk of heart attack.
What the New Study Reveals
Recent research has highlighted a significant, and concerning, outcome for individuals who stop taking a class of drugs known as GLP-1 receptor agonists. A study published in The Lancet Regional Health Europe found that people with type 2 diabetes who discontinued these medications had approximately double the risk of suffering a non-fatal heart attack, a non-fatal stroke, or death from any cause compared to those who continued their treatment. This translates to roughly four major cardiovascular events per 100 people each year among those who stopped, versus two events for those who remained on the medication. Another large study of U.S. veterans with type 2 diabetes, published in BMJ Medicine, showed a similar pattern, finding that after two years off the drugs, the risk of heart attack, stroke, and death was up to 22% higher than in continuous users. These findings suggest that the heart-protective benefits of these drugs are not permanent and can disappear relatively quickly after treatment ceases.
Understanding GLP-1 Drugs
The medications in question are GLP-1 receptor agonists, a class of drugs that have become incredibly popular for managing type 2 diabetes and, more recently, for weight loss. You may know them by brand names such as Ozempic, Wegovy, Rybelsus, Mounjaro, and Zepbound. These drugs work by mimicking a natural hormone called glucagon-like peptide-1. This helps the body regulate blood sugar by stimulating insulin release, suppressing appetite, and slowing down digestion, which promotes a feeling of fullness. Beyond blood sugar control and weight loss, these medications have been proven to offer significant protective benefits for the cardiovascular system. They appear to reduce inflammation, which is a key driver of heart attacks and strokes over time.
Why Does Stopping Increase the Risk?
The protective effects of GLP-1 drugs on the heart and blood vessels appear to be dependent on their continued use. When the medication is stopped, these benefits are lost. Researchers suggest that the cardiovascular protection accumulates slowly over years of use but is lost very rapidly upon discontinuation. This isn't necessarily a 'rebound' in the sense of the drug causing new harm, but rather the loss of a protective shield. Once the drug is no longer present to manage blood sugar, blood pressure, and inflammation, the body's underlying risks for cardiovascular disease are re-exposed. In some cases, this has been termed a 'metabolic rebound', where blood sugar, weight, and blood pressure can worsen and return to pre-treatment levels within about a year. The protection is an active benefit of the drug, not a permanent cure for the underlying condition.
Who Is Most Affected?
The studies primarily focused on patients with type 2 diabetes. One study noted that the increased risk after stopping was even more pronounced in patients who were also living with obesity (a Body Mass Index over 30). While many people without diabetes use these drugs for weight loss, the direct implications for their cardiovascular risk upon stopping are still being studied and require further research. However, the fundamental principle likely remains: obesity itself is a chronic condition, and these medications manage it. When the treatment stops, the underlying condition and its associated risks, including cardiovascular ones, can return. It's also important to note that many patients stop taking these drugs for various reasons, including high costs, bothersome side effects like nausea, or supply shortages, not just because they've reached a health goal.
What Patients and Doctors Should Know
The key message from this research is not that these drugs are dangerous, but that they are treatments for chronic conditions and must be managed as such. The decision to start, and especially to stop, a GLP_1 medication should never be made lightly or without medical supervision. The findings underscore the critical importance of continuous,' uninterrupted treatment to maintain the cardiovascular benefits.' If you are taking one of these medications,' do not stop or alter your dose without first consulting your doctor.' They can discuss the risks and benefits with you,' explore reasons for wanting to stop (such as side effects or cost),' and determine the safest path forward.' This might involve a plan to taper off the drug,' switch to an alternative therapy,' or find ways to manage side effects to ensure continuous treatment.
